Millennium Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-20,000
Closed -$1.49M – 6191
2025
Q2
$1.49M Buy
20,000
+15,000
+300% +$993K ﹤0.01% 4119
2025
Q1
$318K Buy
+5,000
New +$340K ﹤0.01% 5071
2024
Q1
– Sell
-20,000
Closed -$1.71M – 6369
2023
Q4
$1.71M Buy
+20,000
New +$1.73M ﹤0.01% 3731
2023
Q1
– Sell
-15,000
Closed -$1.18M – 6559
2022
Q4
$1.18M Buy
+15,000
New +$1.21M ﹤0.01% 4001
2021
Q3
– Sell
-10,000
Closed -$666K – 6963
2021
Q2
$666K Sell
10,000
-20,000
-67% -$1.42M ﹤0.01% 5041
2021
Q1
$3.33M Hold
30,000
– – ﹤0.01% 3028
2020
Q4
$3.56M Buy
+30,000
New +$3.23M ﹤0.01% 2770

Other funds holding HAE

Millennium Management's HAE Position: Q3 2026 in Review

Millennium Management increased its Haemonetics (HAE) stake by 12% in Q3 2026, buying an estimated $6.19M and bringing the position to 636,895 shares worth $67.1M. The position accounts for 0.02% of the portfolio, ranked #725.

Millennium Management first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $86.6M in Q1 2018. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • Millennium Management held 636,895 shares of Haemonetics worth $67.1M as of Q3 2026.
  • Millennium Management bought 66,482 Haemonetics shares in Q3 2026, an estimated $6.19M.
  • Haemonetics made up 0.02% of Millennium Management's portfolio in Q3 2026, its #725 holding.
  • Millennium Management first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • Millennium Management's Haemonetics position peaked at $86.6M in Q1 2018.
  • 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.